Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G
暂无分享,去创建一个
S. Roy-Chowdhuri | K. Janeway | A. Jaju | B. Weigel | J. V. Tricoli | AeRang Kim | D. Patton | E. Fox | Lauren Saguilig | J. Piao | Brent D. Coffey | N. L. Seibel | Stacey L. Berg | Douglas S Hawkins | P. Williams | Naoko Takebe | Joel M Reid | Marie V Nelson | Todd A Alonzo | Nilsa C Ramirez | Margaret M Mooney | D. W. Parsons | Stacey L Berg
[1] V. Subbiah,et al. Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E-Positive Adult and Pediatric Solid Tumors. , 2023, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[2] B. Geoerger,et al. Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600–Mutant Low-Grade Glioma , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Kathleen B. Cartmell,et al. Trial-level factors affecting accrual and completion of oncology clinical trials: A systematic review , 2021, Contemporary clinical trials communications.
[4] M. Prados,et al. Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002) , 2020, Oncotarget.
[5] J. Chisholm,et al. Tumour-agnostic drugs in paediatric cancers , 2020, British Journal of Cancer.
[6] B. Geoerger,et al. Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study , 2019, Clinical Cancer Research.
[7] C. Pratilas,et al. A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation–Positive Solid Tumors , 2019, Clinical Cancer Research.
[8] I. Matos,et al. Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There? , 2019, Clinical Cancer Research.
[9] Mhcm,et al. Barriers to Patient Enrollment in Therapeutic Clinical Trials for Cancer: A Landscape Report , 2018 .
[10] M. Galsky,et al. Premature Clinical Trial Discontinuation in the Era of Immune Checkpoint Inhibitors. , 2018, The oncologist.
[11] N. André,et al. Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with BRAF V600–mutant relapsed refractory low-grade glioma. , 2018 .
[12] Valérie Rigau,et al. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] R. Gibbs,et al. Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors. , 2016, JAMA oncology.
[14] T. MacDonald,et al. Successful Retreatment of a Child with a Refractory Brainstem Ganglioglioma with Vemurafenib , 2016, Pediatric blood & cancer.
[15] L. McDaniel,et al. Mutation in BRAF and Other Members of the MAPK Pathway in Papillary Thyroid Carcinoma in the Pediatric Population. , 2016, Archives of pathology & laboratory medicine.
[16] G. Leverger,et al. Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis. , 2015, JAMA oncology.
[17] P. Burger,et al. A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation , 2015, Acta Neuropathologica.
[18] Caroline Foster,et al. A Qualitative Study of Recruitment Barriers, Motivators, and Community-Based Strategies for Increasing Clinical Trials Participation among Rural and Urban Populations , 2015, American journal of health promotion : AJHP.
[19] P. Grenier,et al. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Tim Ramsay,et al. Unsuccessful trial accrual and human subjects protections: An empirical analysis of recently closed trials , 2015, Clinical trials.
[21] A. Cacchione,et al. Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent , 2014, Journal of Translational Medicine.
[22] Li Ding,et al. The Genomic Landscape of Childhood and Adolescent Melanoma , 2014, The Journal of investigative dermatology.
[23] Justin C. Earp,et al. FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation , 2014, Clinical Cancer Research.
[24] P. Varlet,et al. Vemurafenib in pediatric patients with BRAFV600E mutated high‐grade gliomas , 2014, Pediatric blood & cancer.
[25] M. Merad,et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups , 2014, The Journal of experimental medicine.
[26] Arie Perry,et al. BRAF-V600E mutation in pediatric and adult glioblastoma. , 2014, Neuro-oncology.
[27] John Y. K. Lee,et al. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas , 2014, Nature Genetics.
[28] D. Gutmann,et al. BRAFV600E mutation is a negative prognosticator in pediatric ganglioglioma , 2013, Acta Neuropathologica.
[29] A. Resnick,et al. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas , 2013, Proceedings of the National Academy of Sciences.
[30] N. Foreman,et al. Brainstem ganglioglioma successfully treated with vemurafenib. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] E. Stites. The Response of Cancers to BRAF Inhibition Underscores the Importance of Cancer Systems Biology , 2012, Science Signaling.
[32] A. Iafrate,et al. BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications , 2011, PloS one.
[33] G. Reifenberger,et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. , 2008, The Journal of clinical investigation.
[34] Phyllis N Butow,et al. Clinical trials in children , 2004, The Lancet.
[35] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[36] M. Kieran. Targeting BRAF in pediatric brain tumors. , 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.